DaVita Inc. · NYSE (us_market)
Healthcare · Medical Care Facilities · United States
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-09-05$137.87 RISE2026-01-14$103.87 PEAK2026-03-26$156.76 202d | -24.7% 131d | 2025-11-19 $115.20 | 2026-03-26 $156.76 | 75Deep Value | 52Value Trap Risk | +50.9% 71d | +36.1% Held 127d |
DROP2025-07-23$151.32 RISE2025-11-19$115.20 PEAK2026-02-17$150.41 209d | -23.9% 119d | 2025-11-19 $115.20 | 2026-02-17 $150.41 | 75Deep Value | 52Value Trap Risk | +30.6% 90d | +30.6% Held 90d |
DROP2024-09-16$165.19 RISE2024-10-31$139.81 PEAK2025-01-30$176.50 136d | -15.4% 45d | Missed | Missed | — | — | +26.2% 91d | Missed |
DROP2023-08-07$112.68 RISE2023-10-13$73.20 PEAK2024-01-10$109.64 156d | -35.0% 67d | 2023-10-13 $73.20 | 2024-01-10 $109.64 | 69Deep Value | 53Deep Value | +49.8% 89d | +49.8% Held 89d |
DROP2022-10-26$99.31 RISE2022-12-20$70.82 PEAK2023-02-02$85.82 99d | -28.7% 55d | 2022-11-16 $69.34 | 2023-02-02 $85.82 | 76Deep Value | 73Deep Value | +21.2% 44d | +23.8% Held 78d |
DROP2022-10-26$99.31 RISE2022-11-09$65.42 PEAK2023-02-02$85.82 99d | -34.1% 14d | 2022-11-16 $69.34 | 2023-02-02 $85.82 | 76Deep Value | 73Deep Value | +31.2% 85d | +23.8% Duplicate trade Held 78d |
DROP2022-04-20$123.38 RISE2022-06-21$76.05 PEAK2022-09-12$95.27 145d | -38.4% 62d | 2022-06-21 $76.05 | 2022-09-12 $95.27 | 76Deep Value | 70Deep Value | +25.3% 83d | +25.3% Held 83d |
DROP2021-08-04$133.78 RISE2021-11-30$94.50 PEAK2022-02-16$120.00 196d | -29.4% 118d | Missed | Missed | — | — | +27.0% 78d | Missed |
DROP2021-01-08$123.89 RISE2021-02-22$99.98 PEAK2021-05-10$127.98 122d | -19.3% 45d | Missed | Missed | — | — | +28.0% 77d | Missed |
DROP2020-02-11$88.50 RISE2020-03-20$64.99 PEAK2020-06-05$88.28 115d | -26.6% 38d | Missed | Missed | — | — | +35.8% 77d | Missed |
DaVita is highlighted as Zacks Bull of the Day, while Arcosa faces pressure from weakening earnings revisions.
DaVita has soared over 70% in 2026 to new highs. The dialysis services giant is projected to double its EPS between 2023 and 2027. Even though it's up 3,000% in the past 25 years, DVA trades at value stock levels.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.
Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.
LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.
DaVita, Integra, Braskem and LyondellBasell screen as attractive GARP stocks, combining growth potential with discounted PEG ratios.
DaVita, Integra, Braskem and LyondellBasell screen as attractive GARP stocks, combining growth potential with discounted PEG ratios.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In recent days, DaVita announced its 2030 Community Care commitments, highlighting goals to empower 150,000 patients through kidney education, support 40,000 transplants, and maintain 100% renewable energy use to bolster care continuity. At the same time, DaVita’s recognition of 57 DAISY Award–winning nephrology nurses and a strong value rating from analysts underscore how workforce investment and perceived valuation strength are shaping perceptions of the company’s long-term resilience...
In recent days, DaVita announced its 2030 Community Care commitments, highlighting goals to empower 150,000 patients through kidney education, support 40,000 transplants, and maintain 100% renewable energy use to bolster care continuity. At the same time, DaVita’s recognition of 57 DAISY Award–winning nephrology nurses and a strong value rating from analysts underscore how workforce investment and perceived valuation strength are shaping perceptions of the company’s long-term resilience...
DaVita (NYSE:DVA) recognized 57 nephrology nurses with the 2026 DAISY Award for Extraordinary Nurses. The awards highlight nursing excellence and patient care within the company's kidney care operations. This recognition focuses on frontline caregivers as a core part of DaVita's service delivery model. For investors watching NYSE:DVA, this update fits within the context of a business built around chronic kidney care and long-term patient relationships. In a sector where staffing remains...
DaVita (NYSE:DVA) recognized 57 nephrology nurses with the 2026 DAISY Award for Extraordinary Nurses. The awards highlight nursing excellence and patient care within the company's kidney care operations. This recognition focuses on frontline caregivers as a core part of DaVita's service delivery model. For investors watching NYSE:DVA, this update fits within the context of a business built around chronic kidney care and long-term patient relationships. In a sector where staffing remains...
MUSA, DVA, MCHP and CVE are near 52-week highs as earnings growth, cash flow strength and expansion plans fuel momentum.
MUSA, DVA, MCHP and CVE are near 52-week highs as earnings growth, cash flow strength and expansion plans fuel momentum.
Nomad Foods is a leading European frozen foods producer with a broad portfolio of well-known brands sold across major supermarket chains.
Nomad Foods is a leading European frozen foods producer with a broad portfolio of well-known brands sold across major supermarket chains.
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, MCHP and CVE are seeing price strength, and the momentum is likely to continue.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DVA | +28.16% | +26.22% | +71.08% | +42.64% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +25.19% | +31.94% | +74.52% | +29.95% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Berkshire | value | 30.10M | $4.63B | 1.76% | Trimmed-5.2% | 2026-03-31 |
| StateStreet | passive | 1.35M | $207.75M | 0.01% | Trimmed-6.0% | 2026-03-31 |
| DEShaw | quant | 504.6K | $77.56M | 0.05% | Unchanged | 2026-03-31 |
| RenTech | quant | 189.2K | $29.08M | 0.05% | Added+10.3% | 2026-03-31 |
| TwoSigma | quant | 49.1K | $7.55M | 0.01% | Added+488.0% | 2026-03-31 |
| FidelityFMR | fundamental | 36.7K | $5.64M | 0.00% | Added+98.5% | 2026-03-31 |
| Citadel | multi-strat | 21.9K | $3.37M | 0.00% | New | 2026-03-31 |
| Bridgewater | macro | 20.9K | $3.21M | 0.01% | Trimmed-40.3% | 2026-03-31 |
| Wellington | fundamental | 2.4K | $364.55K | 0.00% | Trimmed-12.6% | 2026-03-31 |
| TRowePrice | fundamental | 50.5K | $7.76K | 0.00% | Trimmed-2.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | YALE PHYLLIS R | Director | G Gift | 5,038 | — | +$0 |
| 2026-05-18 | HEARTY JAMES O | Chief Compliance Officer | M Option exercise(deriv) | 5,784 | — | +$0 |
| 2026-05-18 | HEARTY JAMES O | Chief Compliance Officer | S Open-market sale | 15,000 | $193.98 | −$2.91M |
| 2026-05-18 | HEARTY JAMES O | Chief Compliance Officer | F Tax withholding | 1,117 | $198.10 | −$221.3K |
| 2026-05-18 | HEARTY JAMES O | Chief Compliance Officer | D Disposition (other) | 3,231 | $198.10 | −$640.1K |
| 2026-05-18 | HEARTY JAMES O | Chief Compliance Officer | M Option exercise | 5,784 | $110.63 | +$639.9K |
| 2026-05-18 | Hollar Jason M. | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | Schechter Adam H | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | DESOER BARBARA J | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | YALE PHYLLIS R | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | Arway Pamela M | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | Schoppert Wendy Lee | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | Moore Gregory J. | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-18 | Pullin Dennis W | Director | A Grant / award | 250 | — | +$0 |
| 2026-05-13 | Maughan David Paul | Chief Operating Officer, DKC | S Open-market sale | 13,456 | $199.25 | −$2.68M |
| 2026-05-13 | Maughan David Paul | Chief Operating Officer, DKC | S Open-market sale | 7,073 | $199.15 | −$1.41M |
| 2026-05-11 | ACKERMAN JOEL | CFO and Treasurer | S Open-market sale | 51,471 | $192.10 | −$9.89M |
| 2026-05-08 | HEARTY JAMES O | Chief Compliance Officer | S Open-market sale | 2,184 | $174.87 | −$381.9K |
| 2026-03-17 | Schoppert Wendy Lee | Director | A Grant / award | 332 | — | +$0 |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | A Grant / award(deriv) | 3,050 | — | +$0 |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | F Tax withholding | 1,525 | $150.72 | −$229.8K |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | F Tax withholding | 300 | $150.72 | −$45.2K |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | F Tax withholding | 8,984 | $150.72 | −$1.35M |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | F Tax withholding | 769 | $150.72 | −$115.9K |
| 2026-03-17 | HEARTY JAMES O | Chief Compliance Officer | A Grant / award | 1,128 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 3.84 | — | — |
| 2026-05-05 | 2.33 | 2.87 | +23.18% |
| 2026-02-02 | 3.19 | 3.40 | +6.51% |
| 2025-10-29 | 3.17 | 2.51 | -20.90% |
| 2025-08-05 | 2.75 | 2.95 | +7.32% |
| 2025-05-12 | 2.02 | 2.00 | -0.95% |
| 2025-02-13 | 2.13 | 2.24 | +5.39% |
| 2024-10-29 | 2.72 | 2.59 | -4.93% |
| 2024-08-06 | 2.63 | 2.59 | -1.36% |
| 2024-05-02 | 1.92 | 2.38 | +23.74% |
| 2024-02-13 | 1.66 | 1.87 | +12.83% |
| 2023-11-07 | 2.04 | 2.85 | +39.89% |
| 2023-08-03 | 1.74 | 2.08 | +19.82% |
| 2023-05-08 | 1.22 | 1.58 | +29.78% |
| 2023-02-22 | 0.98 | 1.11 | +12.79% |
| 2022-10-28 | 1.76 | 1.45 | -17.59% |